Justina Orleans-Lindsay

Pharmacovigilance Medical Writing (eBook, ePUB)

A Good Practice Guide

• Format: ePub

Produktbeschreibung

Pharmacovigilance Medical Writing covers the preparation of pharmacovigilance documents for all stages of the drug development process (i.e. from clinical development through to applications for marketing authorisations to the post-marketing stage). For each document, the book presents a review of the regulatory framework that governs the content of the document, followed by practical guidance (e.g. scheduling, source data, department/functions involved in document preparation/review, appropriate timelines and planning activities), ending with a generic model document compliant with the current guidelines, which can be modified to meet specific company and product requirements.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: John Wiley & Sons
• Seitenzahl: 288
• Erscheinungstermin: 22. Juni 2012
• Englisch
• ISBN-13: 9781118302064
• Artikelnr.: 37351711

Autorenporträt

Justina Orleans-Lindsay BSc, MSc, PhD is a Director of Acadustri (Medical Writing) Limited and Visiting Lecturer in pharmacovigilance at the University of Hertfordshire, UK.

Inhaltsangabe

Preface - Pharmacovigilance Medical Writing Comes of Age ix
Acknowledgements xiii Abbreviations xv 1 Pharmacovigilance Medical Writing
- An Overview Across the Drug Development Process 1 2 Pharmacovigilance
Medical Writing for Clinical Trials 5 2.1 Introduction 5 2.2 The EU Annual
Safety Report and US IND Annual Report - A Historical Look at Reporting
from Clinical Studies 6 2.3 The Development Safety Update Report 9 2.4
References 30 3 Pharmacovigilance Medical Writing for Marketing
Authorization 33 3.1 Introduction 33 3.2 The Summary of Clinical Safety 34
3.3 The Integrated Summary of Safety 60 3.4 The 120-Day Safety Update
Report 73 3.5 References 74 4 Pharmacovigilance Medical Writing in Risk
Evaluation and Management 75 4.1 Introduction 75 4.2 The EU Risk Management
Plan 76 4.3 The Risk Evaluation and Mitigation Strategies Report 96 4.4 The
Benefit-Risk Evaluation Report 106 4.5 References 114 5 Pharmacovigilance
Medical Writing for Marketed Products 117 5.1 Introduction 117 5.2 The EU
Periodic Safety Update Report 119 5.3 The US Periodic Adverse Drug
Experience Report 147 5.4 The PSUR Addendum Report 157 5.5 The Summary
Bridging Report 163 5.6 References 169 6 The Ad-Hoc Safety Review and
Response to Questions Document 171 6.1 Introduction 171 6.2 The Ad-Hoc
Safety Review 172 6.3 The Response to Questions Document 179 7 The Rest of
the World 185 7.1 Introduction 185 7.2 Japan 186 7.3 Canada 188 7.4
Australia and New Zealand 188 7.5 India 189 7.6 Singapore and Taiwan 190
7.7 References 191 Appendices Appendix 1: Sample Line Listing 193 Appendix
2: Sample Summary Tabulation 197 Appendix 3: Another Look at the US IND
Annual Report 199 Appendix 4: The New Pharmacovigilance Legislation in the
EU 211 Appendix 5: The New EU Risk Management Plan 215 Appendix 6: The New
EU Periodic Safety Update Report/Periodic Benefit-Risk Evaluation Report
227 Glossary 253 Index 259

Rezensionen

"This book is well structured and should prove useful for pharmacovigilance scientists and writers to have a reference text and checklist for regulatory pharmacovigilance documentation requirements." -- Pharmaceutical Journal, 9 February 2013